ArticleCureus2026
Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable non-small cell lung cancer (NSCLC). Cisplatin-etoposide (EP) and weekly carboplatin-paclitaxel (PC) are commonly used concurrent regimens, but comparative data on efficacy and toxicity remain limited. This study compared acute treatment-related toxicities and tumor response between these regimens, with six- and 12-month progression-free survival (PFS) and overall survival (OS) evaluated as pre-specified exploratory secondary outcomes. MATERIALS AND
methodsThis prospective randomized study included 34 patients with histologically confirmed unresectable NSCLC treated between April 2021 and June 2022. Patients received either EP (n=16) or PC (n=18) concurrently with definitive radiotherapy (60 Gy in 30 fractions). Acute toxicities and three-month tumor response were evaluated. Kaplan-Meier PFS and OS were estimated separately through six and 12 months in 31 evaluable patients, with horizon-specific log-rank and Cox analyses.
resultsEP produced significantly more severe anemia, thrombocytopenia, and esophagitis, whereas pneumonitis was numerically more frequent with PC. The tumor-response distribution favored EP (p=0.029). Six-month PFS was 66.7% with EP and 56.3% with PC (p=0.499), and 12-month PFS was 40.0% and 25.0%, respectively (p=0.206). Six-month OS was 93.3% with EP and 81.3% with PC (p=0.317), and 12-month OS was 80.0% and 56.3%, respectively (p=0.144).
conclusionsEP was associated with a more favorable tumor-response distribution and numerically better one-year PFS and OS than PC, but the survival differences were not statistically significant. These potential efficacy benefits were accompanied by greater hematological and esophageal toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.